4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

TD Cowen initiated coverage of Septerna with a rating of Buy

Wells Fargo initiated coverage of Septerna with a rating of Overweight and set a new price target of $43.00

Cantor Fitzgerald initiated coverage of Septerna with a rating of Overweight and set a new price target of $50.00

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

3 - Septerna, Inc. (0001984086) (Issuer)

4 - Septerna, Inc. (0001984086) (Issuer)

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins

SC 13D - Septerna, Inc. (0001984086) (Subject)

SC 13G - Septerna, Inc. (0001984086) (Subject)

SC 13G - Septerna, Inc. (0001984086) (Subject)

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism.

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. A live webcast will be available in the Investors & Media section of the company's website at www.septerna.com and will be archived for 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by i

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, with Data Expected in Mid-2025 Well-Capitalized with Balance Sheet to Support a Planned Operating Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today reported financial results for the third quarter ended September 30, 2024 and provided a portfolio overview and busines

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Septerna. The aggregate gross proceeds to Septerna from the IPO were $331.2 million, before deducting underwriting discounts and com